{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:29:11Z","timestamp":1767652151067,"version":"3.38.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.clinthera.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T00:10:17Z","timestamp":1306195817000},"page":"330-345","source":"Crossref","is-referenced-by-count":18,"title":["Iloperidone for the Management of Adults with Schizophrenia"],"prefix":"10.1016","volume":"33","author":[{"given":"Brian L.","family":"Crabtree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.03.006_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1744-859X-6-10","article-title":"Suicide risk in schizophrenia: learning from the past to change the future","volume":"6","author":"Pompili","year":"2007","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2011.03.006_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1993.01820140007001","article-title":"The de facto mental and addictive disorders service system","volume":"50","author":"Regier","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2011.03.006_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0193-953X(18)30182-5","article-title":"The costs of schizophrenia","volume":"16","author":"Rupp","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.clinthera.2011.03.006_bib4","series-title":"Kaplan and Sadock's Comprehensive Textbook of Psychiatry","first-page":"1487","article-title":"Cellular and molecular neuropathology of schizophrenia","author":"Stan","year":"2009"},{"key":"10.1016\/j.clinthera.2011.03.006_bib5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.03.006_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Genl Psychiatry"},{"key":"10.1016\/j.clinthera.2011.03.006_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/jm00007a009","article-title":"3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2\/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873)","volume":"38","author":"Strupczewski","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2011.03.006_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3565(25)20683-8","article-title":"Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2\/5-hydroxytryptamine2 receptor antagonist activity","volume":"278","author":"Szczepanik","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.03.006_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1527-3458.1997.tb00320.x","article-title":"Iloperidone: preclinical profile and early clinical evaluation","volume":"3","author":"Corbett","year":"1997","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.clinthera.2011.03.006_bib10","first-page":"84","article-title":"Iloperidone","volume":"5","author":"Hesselink","year":"2002","journal-title":"IDrugs"},{"key":"10.1016\/j.clinthera.2011.03.006_bib11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0022-3565(25)10685-X","article-title":"The pharmacological profile of iloperidone, a novel atypical antipsychotic agent","volume":"274","author":"Szewczak","year":"1995","journal-title":"J Pharmacol Expl Ther"},{"key":"10.1016\/j.clinthera.2011.03.006_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0014-2999(96)00840-0","article-title":"Iloperidone binding to human and rat dopamine and 5-HT receptors","volume":"317","author":"Kongsamut","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2011.03.006_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/PL00014190","article-title":"Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs","volume":"249","author":"Ichikawa","year":"1999","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2011.03.006_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","article-title":"Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders","volume":"25","author":"Kalkman","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2011.03.006_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2011.03.006_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.03.006_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2006.04.004","article-title":"Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats","volume":"51","author":"Barr","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2011.03.006_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.clinthera.2011.03.006_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/j.1552-4604.1995.tb04112.x","article-title":"Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic","volume":"35","author":"Sainati","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.03.006_bib22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0022-3565(24)37723-7","article-title":"Application of liquid chromatography\/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone","volume":"286","author":"Mutlib","year":"1998","journal-title":"J Pharmacol Expl Ther"},{"key":"10.1016\/j.clinthera.2011.03.006_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0278-5846(01)00307-4","article-title":"Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone","volume":"26","author":"Subramanian","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.03.006_bib24","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"Cutler","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.03.006_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4088\/JCP.08m04391","article-title":"Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia","volume":"70","author":"Volpi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2011.03.006_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/14622416.9.3.289","article-title":"Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial","volume":"9","author":"Lavedan","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2011.03.006_bib27","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/mp.2008.56","article-title":"Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study","volume":"14","author":"Lavedan","year":"2009","journal-title":"Mol Psychiatry"},{"issue":"2 Suppl 1","key":"10.1016\/j.clinthera.2011.03.006_bib28","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"2 Suppl 1","key":"10.1016\/j.clinthera.2011.03.006_bib29","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","article-title":"Long-term efficacy and safety of iloperidone","volume":"28","author":"Kane","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"2 Suppl 1","key":"10.1016\/j.clinthera.2011.03.006_bib30","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials","volume":"28","author":"Weiden","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2011.03.006_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.psychres.2009.03.020","article-title":"Absence of weight gain association with the HTR2C-759C\/T polymorphism in patients with schizophrenia treated with iloperidone","volume":"175","author":"Thompson","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2011.03.006_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2009.02142.x","article-title":"Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialized second-generation antipsychotic","volume":"8","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2011.03.006_bib33","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","first-page":"845","article-title":"Therapy of hypertension","author":"Hoffman","year":"2006"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:35:19Z","timestamp":1741203319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811001469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0149291811001469"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.03.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}